530 related articles for article (PubMed ID: 9384693)
41. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.
Murphy WJ; Back TC; Conlon KC; Komschlies KL; Ortaldo JR; Sayers TJ; Wiltrout RH; Longo DL
J Clin Invest; 1993 Oct; 92(4):1918-24. PubMed ID: 8408644
[TBL] [Abstract][Full Text] [Related]
42. Divergent effects of interleukin-10 on cytokine production by mononuclear phagocytes and endothelial cells.
Sironi M; Muñoz C; Pollicino T; Siboni A; Sciacca FL; Bernasconi S; Vecchi A; Colotta F; Mantovani A
Eur J Immunol; 1993 Oct; 23(10):2692-5. PubMed ID: 8405067
[TBL] [Abstract][Full Text] [Related]
43. Time course and contact dependence of allogeneic lymphocyte-induced human aortic endothelial cell-derived interleukin-6.
Morris TE; Shipley GD; Wagner CR; Hefeneider SH; Hosenpud JD
J Heart Lung Transplant; 1994; 13(6):1081-94. PubMed ID: 7865515
[TBL] [Abstract][Full Text] [Related]
44. Direct in vitro lysis of metastatic tumor cells by cytokine-activated murine vascular endothelial cells.
Li LM; Nicolson GL; Fidler IJ
Cancer Res; 1991 Jan; 51(1):245-54. PubMed ID: 1899041
[TBL] [Abstract][Full Text] [Related]
45. Involvement of immune responses in the eradication of IL-1 alpha gene-transduced tumour cells: mechanisms of tumour rejection and immunotherapeutical implications.
Apte RN; Douvdevani A; Zoller M; White RM; Dvorkin T; Shimoni N; Huleihel M; Fima E; Hacham M; Voronov E
Folia Biol (Praha); 1994; 40(1-2):1-18. PubMed ID: 7958060
[TBL] [Abstract][Full Text] [Related]
46. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome.
Cotran RS; Pober JS; Gimbrone MA; Springer TA; Wiebke EA; Gaspari AA; Rosenberg SA; Lotze MT
J Immunol; 1988 Mar; 140(6):1883-8. PubMed ID: 3279124
[TBL] [Abstract][Full Text] [Related]
47. Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6.
Podor TJ; Jirik FR; Loskutoff DJ; Carson DA; Lotz M
Ann N Y Acad Sci; 1989; 557():374-85; discussion 386-7. PubMed ID: 2660697
[TBL] [Abstract][Full Text] [Related]
48. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.
Birkholz K; Hombach A; Krug C; Reuter S; Kershaw M; Kämpgen E; Schuler G; Abken H; Schaft N; Dörrie J
Gene Ther; 2009 May; 16(5):596-604. PubMed ID: 19158846
[TBL] [Abstract][Full Text] [Related]
49. Regulation of IL-6 expression by oncostatin M.
Brown TJ; Rowe JM; Liu JW; Shoyab M
J Immunol; 1991 Oct; 147(7):2175-80. PubMed ID: 1918953
[TBL] [Abstract][Full Text] [Related]
50. Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release.
Wingren AG; Björkdahl O; Labuda T; Björk L; Andersson U; Gullberg U; Hedlund G; Sjögren HO; Kalland T; Widegren B; Dohlsten M
Cell Immunol; 1996 May; 169(2):226-37. PubMed ID: 8620550
[TBL] [Abstract][Full Text] [Related]
51. Augmentation of interleukin-6 (IL-6) expression in squamous carcinoma cells and normal human keratinocytes treated with recombinant anti-neoplastic protein (ACP).
McKenzie RC; Venner TJ; Sauder DN; Farkas-Himsley H
Anticancer Res; 1994; 14(3A):1165-8. PubMed ID: 8074468
[TBL] [Abstract][Full Text] [Related]
52. Breast cancer gene therapy: transgenic immunotherapy.
Su N; Ojeifo JO; MacPherson A; Zwiebel JA
Breast Cancer Res Treat; 1994; 31(2-3):349-56. PubMed ID: 7881111
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13.
Serve H; Oelmann E; Herweg A; Oberberg D; Serve S; Reufi B; Mücke C; Minty A; Thiel E; Berdel WE
Cancer Res; 1996 Aug; 56(15):3583-8. PubMed ID: 8758930
[TBL] [Abstract][Full Text] [Related]
54. In vivo effects of recombinant human interleukin 6, alone or in combination with local irradiation, on tumor growth in Lewis lung carcinoma-bearing mice.
Lu L; Shen RN; Broxmeyer HE
Int J Cell Cloning; 1991 Sep; 9(5):511-20. PubMed ID: 1955739
[TBL] [Abstract][Full Text] [Related]
55. Mast cell granules potentiate endotoxin-induced interleukin-6 production by endothelial cells.
Li Y; Stechschulte AC; Smith DD; Lindsley HB; Stechschulte DJ; Dileepan KN
J Leukoc Biol; 1997 Aug; 62(2):211-6. PubMed ID: 9261335
[TBL] [Abstract][Full Text] [Related]
56. In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.
McIntosh JK; Jablons DM; Mulé JJ; Nordan RP; Rudikoff S; Lotze MT; Rosenberg SA
J Immunol; 1989 Jul; 143(1):162-7. PubMed ID: 2499626
[TBL] [Abstract][Full Text] [Related]
57. Thioredoxin as a potent costimulus of cytokine expression.
Schenk H; Vogt M; Dröge W; Schulze-Osthoff K
J Immunol; 1996 Jan; 156(2):765-71. PubMed ID: 8543831
[TBL] [Abstract][Full Text] [Related]
58. Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells.
Kobayashi M; Shimada K; Ozawa T
J Cell Physiol; 1990 Sep; 144(3):383-90. PubMed ID: 2202741
[TBL] [Abstract][Full Text] [Related]
59. Are interleukin-2 and interleukin-15 tumor promoting factors for human non-hematopoietic cells?
Azzarone B; Pottin-Clemenceau C; Krief P; Rubinstein E; Jasmin C; Scudeletti M; Indiveri F
Eur Cytokine Netw; 1996; 7(1):27-36. PubMed ID: 8704093
[TBL] [Abstract][Full Text] [Related]
60. Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities.
Damia G; Komschlies KL; Futami H; Back T; Gruys ME; Longo DL; Keller JR; Ruscetti FW; Wiltrout RH
Cancer Res; 1992 Aug; 52(15):4082-9. PubMed ID: 1638519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
